🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Wenjin Yin clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Wenjin Yin as lead sponsor. Synced 26 Sep 2026
8Current trials
5Recruiting now
4Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Wenjin Yin is the lead sponsor of 8 current clinical trials in our China register. 5 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Fulvestrant, Iparomlimab and Tuvonralimab and Pyrotinib. The most-studied condition is Advanced Breast Cancer.

ClinicalTrials.gov trials by status

  • Recruiting563%
  • Active, closed338%

Trials by phase

  • Observational563%
  • Phase 2225%
  • Not applicable113%
01

Clinical trials sponsored by Wenjin Yin

8 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Capecitabine and Cyclophosphamide (XC) as Maintenance Therapy for Advanced Breast Cancer
NCT05876065 · ClinicalTrials.gov ↗ · Advanced Breast Cancer
Not applicable Recruiting 2023-06 China
Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
NCT07180082 · ClinicalTrials.gov ↗ · Advanced Breast Cancer
Drug: Pyrotinib
Phase 2 Recruiting 2025-08 China
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
NCT07180160 · ClinicalTrials.gov ↗ · Advanced Breast Cancer
Phase 2 Recruiting 2025-09 China
Adjuvant CDK4/6 Inhibitor Use in HR+/HER2- Breast Cancer
NCT07180056 · ClinicalTrials.gov ↗ · Breast Cancer
Observational Recruiting 2025-08 China
Trastuzumab Deruxtecan in Advanced Breast Cancer
NCT07180264 · ClinicalTrials.gov ↗ · Advanced Breast Cancer
Observational Recruiting 2025-08 China
The Association Between Blood Routine Parameters and Breast Cancer Prognosis
NCT07584213 · ClinicalTrials.gov ↗ · Breast Cancer Invasive
Observational Active, closed 2026-05 China
The Association Between Axillary Lymph Node Metastasis Patterns and Breast Cancer Prognosis
NCT07283718 · ClinicalTrials.gov ↗ · Breast Cancer Invasive
Observational Active, closed 2025-09 China
The Association of Lunula Status With the Efficacy and Safety of Neoadjuvant Therapy in Breast Cancer
NCT07590570 · ClinicalTrials.gov ↗ · Breast Cancer Invasive
Observational Active, closed 2026-05 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Wenjin Yin trials

4 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Wenjin Yin trials

3 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China85

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced Breast Cancer

SponsorTrials
Xuanzhu Biopharmaceutical2
Beijing Biostar Pharmaceuticals1
CSPC Ouyi Pharmaceutical1
CSPC Megalith Biopharmaceutical1

Sponsors with the most current trials registered for this condition.

06

Questions about Wenjin Yin trials

How many clinical trials does Wenjin Yin sponsor?

Wenjin Yin is the lead sponsor of 8 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Wenjin Yin trials recruiting?

Yes. 5 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Wenjin Yin testing?

Its current trials name 4 drugs and biologicals as interventions. The most frequent are Fulvestrant (1), Iparomlimab and Tuvonralimab (1), Pyrotinib (1) and Trastuzumab deruxtecan (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.